Identifying Abnormal Exertional Breathlessness in COPD: Comparing Modified Medical Research Council and COPD Assessment Test With Cardiopulmonary Exercise Testing
- PMID: 39490971
- PMCID: PMC11882773
- DOI: 10.1016/j.chest.2024.10.027
Identifying Abnormal Exertional Breathlessness in COPD: Comparing Modified Medical Research Council and COPD Assessment Test With Cardiopulmonary Exercise Testing
Abstract
Background: COPD management is guided by the respiratory symptom burden, assessed using the modified Medical Research Council (mMRC) scale, the COPD Assessment Test (CAT), or both.
Research question: What are the abilities of mMRC and CAT to detect abnormally high exertional breathlessness on incremental cardiopulmonary cycle exercise testing (CPET) in people with COPD?
Study design and methods: Analysis of people aged ≥ 40 years with FEV1 to FVC ratio of < 0.70 after bronchodilator administration and ≥ 10 pack-years of smoking from the Canadian Cohort Obstructive Lung Disease study. Abnormal exertional breathlessness was defined as a breathlessness (Borg scale 0-10) intensity rating more than the upper limit of normal at the symptom-limited peak of CPET using normative reference equations.
Results: We included 318 people with COPD (40% female) with a mean (SD) age of 66.5 (9.3) years and FEV1 of 79.5% predicted (19.0% predicted); 26% showed abnormally low exercise capacity (peak oxygen uptake less than the lower limit of normal). Abnormally high exertional breathlessness was present in 24%, including 9% and 11% of people with mMRC score of 0 and CAT score of < 10, respectively. An mMRC score of ≥ 2 and CAT score of ≥ 10 was most specific (95%) to detect abnormal exertional breathlessness, but showed low sensitivity of only 12%. Accuracy for all scale cutoffs or combinations was < 65%. Compared with people with true-negatives findings, people with abnormal exertional breathlessness but low mMRC score, low CAT scores (false-negatives findings), or both showed worse self-reported and physiologic outcomes during CPET, were more likely to have physician-diagnosed COPD, but were not more likely to be taking any respiratory medication (37% vs 30%; mean difference, 6.1%; 95% CI, -7.2 to 19.4; P= .36).
Interpretation: In COPD, mMRC and CAT showed low concordance with CPET and failed to identify many people with abnormally high exertional breathlessness.
Clinical trial registry: ClinicalTrials.gov; No.: NCT00920348; URL: www.
Clinicaltrials: gov.
Keywords: dyspnea; exercise capacity; exercise test; reference values.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: J. B. and W. C. T. report receiving institutional funding for the CanCOLD study from Astra Zeneca Canada, Ltd., Boehringer-Ingelheim Canada, Ltd., GlaxoSmithKline Canada, Ltd., Merck, Novartis Pharma Canada, Inc., as well as Nycomed Canada, Inc. (W. C. T.), Pfizer Canada, Ltd. (W. C. T.), Trudell (J. B.), and Grifolds (J. B.). Unrelated to this work, M. E. has received a research grant from ResMed and personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche. None declared (H. L., P. Z. L., D. J.).
Figures



References
-
- Nishimura K., Izumi T., Tsukino M., et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121(5):1434–1440. - PubMed
-
- Bourbeau J., Bhutani M., Hernandez P., et al. 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD. Chest. 2023;164(5):1159–1183. - PubMed
-
- Ramon M.A., Ter Riet G., Carsin A.E., et al. The dyspnoea-inactivity vicious circle in COPD: development and external validation of a conceptual model. Eur Respir J. 2018;52(3):1800079. - PubMed
Publication types
MeSH terms
Associated data
LinkOut - more resources
Miscellaneous